Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: 681323; GSK 681323; SB 681323

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Class Analgesics; Anti-inflammatories; Antibronchitics; Antirheumatics; Pyrimidines; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute lung injury; Adult respiratory distress syndrome; Atherosclerosis; Chronic obstructive pulmonary disease; Neuropathic pain; Rheumatoid arthritis

Most Recent Events

  • 16 Sep 2009 Efficacy, adverse event and pharmacodynamics data from a phase II trial in Chronic obstuctive pulmonary disease presented at the 19th Annual Congress of the European Respiratory Society (ERS-2009)
  • 06 Dec 2005 Phase-II clinical trials in Atherosclerosis in the UK
  • 30 Nov 2005 Phase-II clinical trials in Rheumatoid arthritis (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top